OQROGet OQRO Pro
Politician trade (House)

AbbVie (ABBV)Rep. Ritchie John Torres (NY15) disclosed a sale $1K–$15K

Rep. Ritchie John Torres (NY15) disclosed a sale of AbbVie in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
40 days
Disclosure lag
Traded
Jul 11, 2025
Disclosed
Aug 20, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 26, 2024CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  2. Apr 1, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  3. Apr 3, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  4. Apr 17, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  5. May 14, 2025FDAFDA drug approval: Emrelis
  6. May 15, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  7. May 22, 2025FDAFDA drug approval: Lupron Depot-Ped Kit
  8. May 22, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  9. Jun 10, 2025FDAFDA drug approval: Mavyret
  10. Jun 10, 2025FDAFDA drug approval: Mavyret
  11. Jun 17, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  12. Jul 11, 2025 · this disclosureCongressDisclosed sale of ABBV — reported range $1,001 - $15,000

What came next

  1. Jul 22, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  2. Aug 4, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  3. Aug 5, 2025Insider · 1 personInsiders: 2 sales (~$2.6M)
  4. Aug 11, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  5. Aug 12, 2025InsiderOfficer sold ~$8.41M of ABBV shares in the open market
  6. Aug 14, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  7. Aug 22, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  8. Sep 3, 2025FDAFDA drug approval: Skyrizi
  9. Sep 3, 2025FDAFDA drug approval: Skyrizi
  10. Oct 3, 2025Company filing · Form 8-K · ResultsReported its results
  11. Oct 10, 2025FDAFDA drug approval: Rinvoq
  12. Oct 31, 2025Company filing · Form 8-K · ResultsReported its results
  13. Nov 4, 2025FDAFDA drug approval: Linzess
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for AbbVie

For AbbVie, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 130 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

Other recent filings by Rep. Ritchie John Torres (NY15)

The full history of Rep. Ritchie John Torres (NY15) is on the profile page.

How this filing works

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data